Pre-made Onartuzumab benchmark antibody ( Fab + di-Fc, anti-MET therapeutic antibody, Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-401-1mg	1mg	Inquiry
GMP-Bios-ab-401-10mg	10mg	Inquiry
GMP-Bios-ab-401-100mg	100mg	Inquiry
GMP-Bios-ab-401-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
INN Name	Onartuzumab
Target	MET
Format	Fab + di-Fc
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	4k3j:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Chugai Pharmaceutical;Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours
Development Tech	na